1. Introduction {#sec1}
===============

The peculiar characteristics of paclitaxel (PTX), a tricyclic diterpenoid isolated from the Pacific or Western yew tree *Taxus brevifolia*, make this natural compound one of the most useful and effective chemotherapeutic drugs available, effective against a broad spectrum of tumors ([@bib2]). In particular, this compound plays a crucial role in the treatment of ovarian, cervical and breast cancers, as well as non-small cell lung cancer, Kaposi\'s sarcoma and acute leukemia ([@bib31]). It is a microtubule-stabilizing compound that selectively disrupts microtubule dynamics, binding with high affinity to the β subunit of tubulin, which causes the distortion of the cytoskeletal structure and consequent mitotic arrest in the G~2~ and M phases of the cell cycle, triggering apoptosis in proliferating cancer cells ([@bib38]). The combination of both antiproliferative and cytotoxic properties contributes to the antitumor efficacy of PTX. Unfortunately, like many other anticancer drugs, its clinical use is greatly limited by various drawbacks, including poor water solubility, low bioavailability and poor tumor localization. To overcome these problems, PTX was formulated with Cremophor EL and dehydrated ethanol Taxol® for parenteral administration in patients, but the presence of the organic solvent induced severe side effects in 20--40% of them such as allergies, hypersensitivity and anaphylactic reactions, compromising the therapeutic index of the drug ([@bib45]). Therefore, various biocompatible formulations were developed in order to avoid the use of organic solvents and Abraxane (PTX-loaded albumin nanoparticles) was approved in 2005 for human use ([@bib26]). This formulation mitigated the side effects associated with the use of Cremophor EL and significantly enhanced the antitumor efficacy of PTX ([@bib16]). However, despite the biocompatibility of the human albumin protein it contains, this formulation has only moderately increased the bioavailability and safety of PTX because it continues to cause side effects such as hair loss, weakness, decreases in the red blood cell count and joint and muscle pain ([@bib42]). In addition to Abraxane, paclitaxel is also marketed on two other nanoplatforms for parenteral administration, liposomes (Lipusu®) and polymeric micelles, namely Genexol®PM ([@bib46]), Nanoxel® ([@bib25]) and Paclical® ([@bib43]). In the last decade, other types of nanoencapsulation have been performed in order to modulate the biopharmaceutical properties of PTX and various systems are under investigation at the moment ([@bib13]; [@bib42]).

Among these, biodegradable polymeric nanoparticles have aroused a considerable amount of interest due to their biocompatibility, their capacity to retain either hydrophilic or hydrophobic drugs, their significant stability and the possibility of being administered by way of different routes ([@bib44]). Moreover, the colloidal size and ample surface area can promote their interaction with aqueous media, favoring the localization of the entrapped compounds inside the tumor by means of their enhanced permeation and retention (EPR) effects when they are circulating in the blood stream ([@bib17]). In addition, nanoparticles can modulate the function of the drug efflux pumps of the cancer cells, promoting the decrease of multidrug resistance as was true in the case of polyalkylcyanoacrylates ([@bib18]).

Among the polymeric nanoparticles, protein-based nanosystems have been used to entrap various active compounds with the aim of increasing their pharmacological activity and decreasing their side effects; in particular, plant proteins have been widely investigated because they are considered "environmentally economic" as compared to animal proteins, due to the minimum natural resources required for their preparation ([@bib19]).

Zein, for example, a protein of corn, has been used for the development of nanoparticles because it is characterized by useful physico-chemical properties for drug delivery applications ([@bib34]). It received the "GRAS" status thanks to its biodegradability, biocompatibility, low immunogenicity and its continually renewable and inexpensive source ([@bib5]).

Zein is a highly hydrophobic protein with a peculiar bricklike shape able to retain lipophilic compounds such as essential oils ([@bib36]), vitamin D3 ([@bib29]), resveratrol ([@bib23]), or carotenoids ([@bib24]). The encapsulation of anticancer compounds within zein nanoparticles can promote their accumulation in solid tumors by the enhanced permeability and retention effect related to the capillary fenestrations of leaky tumor vasculature ([@bib19]). Lai and coworkers demonstrated that 5-Fluorouracil-loaded zein nanosystems mostly accumulated in the liver following intravenous injection, increasing the drug localization by 31.33% ([@bib27]). Recently, Dong et al. demonstrated that doxorubicin can be successfully encapsulated into zein nanoparticles reaching a loading capacity of 15.01 mg of drug per gram of protein ([@bib17]). Our research team recently proved that it is possible to combine raw zein-nanoparticles and various surfactants, demonstrating that sodium deoxycholate (SD) can dramatically stabilize the colloidal structure ([@bib20]). The aim of the present work was to encapsulate PTX within SD decorated-zein nanoparticles, characterizing the nanosystems as a function of storage period, temperature and pH. Moreover, the drug entrapment efficiency and the stability of the formulations after serum incubation and the freeze-drying process were evaluated. Finally, the toxicity of PTX-loaded zein nanoparticles on two cancer cell lines (MCF-7 and K562) was investigated with respect to the free form of the drug.

2. Materials & methods {#sec2}
======================

2.1. Materials {#sec2.1}
--------------

Yellow zein, sodium deoxycholate monohydrate (SD), 3-\[4,5-dimethylthiazol-2-yl\]-3,5-diphenyltetrazolium bromide salt (used for MTT-tests), phosphate buffered saline (PBS) tablets, dimethyl sulfoxide, and amphothericin B solution (250 μg/ml) were all purchased from Sigma Aldrich (Milan, Italy). Paclitaxel (PTX) was kindly provided by Indena S.p.a. (Milan, Italy). \[^3^H\]cholesteryl hexadecyl ether (\[^3^H\]CHE, 40 Ci/mmoL) was obtained from Perkin Elmer-Italia (Monza, Italy).

For the *in vitro* studies, DMEM (Dulbecco\'s Modified Eagle\'s Medium) and RPMI1640 enriched with Glutamax I, tripsin/EDTA, penicillin/streptomycin solution and fetal bovine serum (FBS) were obtained from GIBCO (Life Technology, Milan, Italy). Human breast cancer cells (MCF-7) and chronic myelogenous leukemia (K562) were provided by the IRCCS Azienda Ospedaliera Universitaria San Martino -- IST Istituto Nazionale per la Ricerca sul Cancro. All other materials and solvents used in this investigation were of analytical grade (Carlo Erba, Milan, Italy).

2.2. Preparation of zein nanoparticles {#sec2.2}
--------------------------------------

The zein nanoparticles were prepared according to the nanoprecipitation method of the pre-formed polymer in an aqueous solution as previously described ([@bib20]). Briefly, 10 mg of zein were dissolved in 3 ml of an ethanol/water solution (2:1 v/v) at room temperature and added to 5 ml of aqueous phase made up of MilliQ water containing 1.25% w/v of SD, homogenized using an Ultraturrax® (model T25, IKA® Werke) at 24000 rpm for 1 min and then mechanically stirred at 600 rpm for 12 h on a magnetic plate to favor the evaporation of the organic solvent ([@bib20]).

Zein nanoparticles containing PTX were obtained by adding different amounts of the drug to the organic phase. Successively, the colloidal formulations were centrifuged at 90 k rpm for 1 h using a Beckman Optima™ Ultracentrifuge (Fullerton, Canada) in order to perform the analytical investigations, or suitably purified by means of Amicon® Ultra centrifugal filters (cut-off 10kDa, 4000 rpm for 120 min) before the cytotoxicity experiments *in vitro*.

2.3. Physico-chemical characterization {#sec2.3}
--------------------------------------

A Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, United Kingdom, a dynamic light scattering apparatus), was used to evaluate the mean diameter, size distribution and Z-potential of the nanosystems by applying the third-order cumulant fitting correlation function as previously described ([@bib35]). The results were expressed as the mean of three different experiments ± standard deviation.

The formulations were also submitted to Turbiscan Lab® Expert analysis (Formulaction, Toulouse, France) with the aim of investigating their stability profiles as a function of temperature and storage time ([@bib12]). The data was processed using a Turby Soft 2.0 and reported as Turbiscan Stability Index (TSI) versus time.

2.4. Effect of pH, temperature and serum on the stability of nanosystems {#sec2.4}
------------------------------------------------------------------------

The nanoformulations (1 ml samples contained in glass Pyrex test tubes) were incubated in a water bath for 1 h at fixed temperatures ranging from 30 to 50 °C. Successively, the particle sizes, polydispersity indexes and zeta-potentials were evaluated. Moreover, the influence of pH on the modulation of the physico-chemical properties of various zein-based formulations was studied by dispersing the samples (dilution 1:50) in deionized water at different pH values (4.0, 6.0, 8.0, 10.0, by a pHmeter SevenCompact S210 Mettler Toledo), using 1 mol/l NaOH or HCl, for 1 h under slow, continuous stirring at room temperature.

The stability of PTX-loaded zein nanoparticles in serum was investigated following their incubation in 70% of FBS ([@bib15]). In detail, 200 μl samples of the formulations were added to 1 mL of FBS and incubated at 37 °C for 48 h, while undergoing stirring at 600 rpm. The samples were analyzed at different incubation times (0,5, 1, 2, 3, 4, 6, 24 and 48 h) and their average size was measured as previously reported.

2.5. Entrapment efficiency of PTX {#sec2.5}
---------------------------------

The amount of PTX retained by each type of colloidal structure was evaluated through HPLC analysis using a Thermo Scientific (Rodano, MI, Italy) Dionex Ultimate 3000, equipped with a 25 cm × 4.6 mm Thermo Scientific Hypersil GOLD C18 column packed with 5 μm particles.

Briefly, the pellet of ultracentrifuged purified nanoparticles was freeze-dried and incubated for 12 h in ethanol in order to promote the release of PTX. The samples were then filtered through a 0.2 μm membrane, transferred to amber vials and analyzed through HPLC ([@bib28]).

An isocratic method was used. The mobile phase was composed of 40% of solvent A (an aqueous solution of trifluoroacetic acid, pH = 2.4) and 60% of solvent B (Acetonitrile) at a flow rate of 1 ml min^−1^, while the injected volume was 20 μl. The chromatograms were acquired at 230 nm by a UV detector.

A calibration curve was determined using standard solutions of PTX in EtOH (0.05--10 ppm of drug). The entrapment efficiency (EE%) was expressed as the percentage of the total amount of drug that became entrapped, according to the following equation:where De is the amount of entrapped drug and Da is the amount of PTX added during the preparation of the systems.

The loading capacity (LC%) was expressed as the percentage of the ratio between the amount of total entrapped drug and the total weight of the nanoparticles. The amount of SD integrated into the structure was evaluated using a colorimetric method as the difference between the concentration of the compound contained in the supernatant of the samples following centrifugation and that initially added during the preparation of the formulations ([@bib41]).

The amount of PTX released from the zein nanoparticles was evaluated by means of the dialysis method using cellulose acetate dialysis tubing (Spectra/Por with molecular cutoff 12,000--14,000 by Spectrum Laboratories Inc.) as previously described ([@bib13]). A PBS solution (pH 7.4, 0.1 M, 10% v/v EtOH) constantly stirred and warmed to 37 ± 0.1 °C was used as the release fluid for the active compound. The percentage of released PTX was calculated using the following equation:where drug~rel~ is the amount of drug released at the time t and drug~load~ is the amount of drug entrapped within the zein nanoparticles.

2.6. Freeze-drying of nanosystems {#sec2.6}
---------------------------------

PTX-loaded zein nanoparticles were lyophilized by freeze-drying (VirTis SP scientific sentry 2.0) equipped with a vacuum pump (Carpanelli S.p.a, B14 model). Briefly, 0.5 ml of formulation was enriched with various concentrations (5 and 10% w/v) of different cryoprotectants as previously described, transferred to pyrex glass vials and frozen in liquid nitrogen for 2 minutes ([@bib20]). Successively, samples were placed in the freeze-drying chamber and subjected to a cryo-drying process for 24 hours. The temperature of the condenser was approximately -55 °C, while the pressure was approximately 30--50 mTorr. At the end of the procedure the resulting powder was rehydrated with the same volume of sublimated water by manual shaking and then the sizes and surface charges were evaluated through dynamic light scattering (see section [2.3](#sec2.3){ref-type="sec"}.).

2.7. Cell cultures and *in vitro* cytotoxicity {#sec2.7}
----------------------------------------------

MCF-7 (breast cancer cell lines) and K562 cells (human chronic myelogenous leukemia cells) were incubated in plastic culture dishes (100 mm × 20 mm) in a water-jacketed CO~2~ incubator at 37 °C (5% CO~2~) using a D-MEM with glutamine and RPMI1640, respectively, supplemented with penicillin (100 UI/ml), streptomycin (100 ug/ml), amphotericin B (250 ug/ml) and FBS (10%, v/v) as previously described ([@bib13]; [@bib10],[@bib14]).

MTT-assay was used to evaluate cell viability after incubation with PTX as free form (solubilized in ethanol) or encapsulated in zein nanoparticles and the investigation was performed as a function of the drug concentrations (0.01--1 μM) and incubation times (24, 48 and 72 h). The untreated cells were used as control while the cells treated with empty zein nanosystems or ethanol (at the same concentration as the formulations containing PTX) were used as the blank. Successively, 20 μl of tetrazolium salt solubilized in phosphate buffered solution (5 mg/mL) were added to each well, the plates were incubated again for 3 hours and then analyzed using a microplate spectophotometer (xMARK™−BIORAD) at a wavelength of 540 nm with reference at 690 nm. Cell viability, expressed as a percentage, was reported as the mean of five different experiments ± standard deviation and was obtained through the following equation, in which AbsT is the absorbance of treated cells and AbsC is the absorbance of control (untreated) cells:

2.8. Interaction of tritiated zein nanoparticles with cells {#sec2.8}
-----------------------------------------------------------

The rate of interaction between the SD-stabilized zein nanoparticles and the cell lines (K562 and MCF-7) as a function of incubation times was investigated as previously described ([@bib14]). Briefly, \[^3^H\]CHE-radiolabeled (0.003% w/w with respect to the amount of zein) nanosystems were prepared, centrifuged (80000 × g for 30 minutes at 4 °C) and resuspended in a suitable medium before each investigation in order to prevent the interference related to the \[^3^H\]CHE molecules that were not integrated into the structures of the nanoparticles. The cells were plated in six-well culture dishes (5 × 10^5^ cells/mL) and treated with 25 μL of tritiated formulation at different incubation times. Successively, they were centrifuged, washed, transferred into polypropylene liquid scintillation vials (20 mL size) (Sigma-Aldrich Chemie, GmbH, Steinheim, Germany) and dissolved in 2 mL of H~2~SO~4~ (96%). A liquid scintillation cocktail (Ready Organic, Beckman Coulter Inc, Fullerton, CA) was added to each vial and the samples analyzed using a Wallac Win Spectral 1414 liquid scintillation counter (PerkinElmer Life and Analytical Sciences Inc, Waltham, MA). Untreated cells were used as control.

2.9. Statistical analysis {#sec2.9}
-------------------------

The statistical analysis of the various experiments was performed by ANOVA and results confirmed by a Bonferroni t-test, with a p value of \<0.05 considered statistically significant.

3. Results and discussion {#sec3}
=========================

3.1. Physicochemical and technological characterization {#sec3.1}
-------------------------------------------------------

Zein nanoparticles were recently developed and characterized by our research team. These colloidal systems had a protein concentration of 2 mg/ml, an absence of aggregates and a suitable mean diameter ([@bib20]). Moreover, the use of SD (1.25% w/v) significantly increased the stability of the nanoparticles with respect to other hydrophilic surfactants, modulated the surface charges of the nanosystems (from positive to negative values) and favored a good degree of retention of the various compounds, showing properties of colloidal systems suitable for possible systemic administration ([Table 1](#tbl1){ref-type="table"}) ([@bib20]).Table 1Composition and physico-chemical properties of zein nanoparticles.Table 1SampleCodeZein (mg/ml)Stabilizer (% w/v)[a](#tbl1fna){ref-type="table-fn"}Mean sizes (nm)Polydispersity IndexZeta potential (mV)Surfactant freeA0.2--450 ± 120.22 ± 0.15-15 ± 1B0.4--317 ± 120.27 ± 0.01-3 ± 1C0.6--146 ± 10.24 ± 0.016 ± 2D0.8--135 ± 10.25 ± 0.019 ± 1E1--126 ± 20.21 ± 0.0114 ± 1F2--101 ± 10.18 ± 0.0121 ± 1G3--151 ± 50.58 ± 0.0428 ± 1T80[a](#tbl1fna){ref-type="table-fn"}H21.25289 ± 22\*0.55 ± 0.0710 ± 1\*\*I22.5131 ± 1\*\*0.18 ± 0.0112 ± 1\*\*L25125 ± 3\*\*0.27 ± 0.0111 ± 2\*\*PLX188[b](#tbl1fnb){ref-type="table-fn"}M21.25102 ± 30.24 ± 0.0322 ± 1N22.5100 ± 20.19 ± 0.0134 ± 5\*O2590 ± 10.15 ± 0.0121 ± 2SD[c](#tbl1fnc){ref-type="table-fn"}P21.25105 ± 10.15 ± 0.01-32 ± 2\*\*Q22.5320 ± 106\*0.46 ± 0.05-40 ± 1\*\*R25\>1000\*\*0.76 ± 0.17-35 ± 5\*\*[^1][^2][^3][^4]

Considering this data, the initial step of the present work was focused on the evaluation of the physico-chemical parameters of SD-stabilized zein nanoparticles prepared with various concentrations of PTX. [Table 2](#tbl2){ref-type="table"} shows the results of the DLS analysis; in detail, the zein nanoparticles had an average diameter of less than 200 nm, a low polydispersity index representing a narrow size distribution of the nanosystems, and a surface charge of about -30 mV, ideal for the stability of the colloids over time ([@bib3]; [@bib4]). The addition of PTX to the organic phase resulted in a slight increase of the average diameter and size distribution of the zein nanoparticles which was proportional to the concentration of the drug used, probably because the encapsulation of the lipophilic compounds present in the zein nanosystems enhances intra-particle attraction and aggregation ([@bib6]). Contrarily, the surface charges of the nanosystems were not strongly affected by the anticancer drug, probably because the active compound did not significantly modulate the protein arrangement ([@bib28]).Table 2Physico-chemical properties of PTX-loaded SD-stabilized-zein nanoparticles.Table 2PTX concentration (μg/ml)Mean Sizes (nm)Polydispersity IndexZeta Potential (mV)-110 ± 20.11 ± 0.01-32 ± 0.5100103 ± 60.19 ± 0.01-32 ± 0.5200131 ± 6\*\*0.18 ± 0.08-28 ± 2.2300158 ± 5\*\*0.21 ± 0.04-31 ± 2.0**After 12 months of storage at 4 °C**[a](#tbl2fna){ref-type="table-fn"}-115 ± 10.14 ± 0.01-28 ± 0.8100118 ± 70.12 ± 0.01-25 ± 1.6200133 ± 6\*0.16 ± 0.08-23 ± 1.8300163 ± 5\*\*0.18 ± 0.04-27 ± 2.2[^5][^6]

On the other hand, the SD-free formulation did not evidence a great propensity to interact with the lipophilic compound because an increase in the polydispersity, macroaggregates and significant sedimentation was manifested when PTX was added to the protein during preparation ([Table 3](#tbl3){ref-type="table"}).Table 3Physico-chemical properties of PTX-loaded SD-free zein nanoparticles.Table 3PTX concentration (μg/ml)Mean Sizes (nm)Polydispersity IndexZeta Potential (mV)-110 ± 20.13 ± 0.0118 ± 2100126 ± 6\*0.25 ± 0.0515 ± 3200161 ± 9\*\*0.34 ± 0.0920 ± 4300265 ± 12\*\*0.45 ± 0.116 ± 5[^7]

It was interesting to note that the average size, polydispersity index and Zeta-potential showed no significant changes for up to 12 months of storage at 4 °C ([Table 2](#tbl2){ref-type="table"}). This is a desirable feature because once again the great stabilization of the colloidal provided by the ionic surfactant was confirmed.

During the physico-chemical characterization of a drug delivery system, the influence of the temperature on the stability of the formulation is an important parameter to be evaluated. This analysis was carried out using a Turbiscan Lab® Expert apparatus able to correlate the transmittance and backscattering of a sample as a function of time and temperature ([@bib8]). The advantage of this instrument, compared to conventional methods of analysis, consists in the possibility of quickly determining the stability of a colloidal system ([@bib12],[@bib11]), with a high degree of precision, and with no mechanical destruction or manipulation of the sample.

The zein nanoparticles containing the anticancer drug were analyzed at room temperature (20 °C) and at body temperature (37 °C) with the aim of evaluating the effects of PTX on their stability. As can be seen in [Fig. 1](#fig1){ref-type="fig"}, the encapsulation of different amounts of the active compound did not result in a marked variation of the TSI with respect to the empty nanosystems. This data is related to the ΔBS and ΔT profiles of the various formulations which were very similar ([Fig. 2](#fig2){ref-type="fig"}).Fig. 1TSI of zein nanoparticles prepared with various amounts of PTX as a function of time (t0: panels a and b; after 12 months: panels c and d) and temperature (20 °C: panels a and c; 37 °C: panels b and d).Fig. 1Fig. 2ΔT and BS profiles of empty SD-zein nanoparticles (A) and of nanosystems prepared with various amounts of PTX (B: 100 μg/ml; C: 200 μg/ml; D: 300 μg/ml) using Turbiscan Lab. The result was a representative experiment of three independent experiments.Fig. 2

The investigation of the TSI values of the various formulations was carried out for 30 days showing only a little variation with respect to those obtained immediately after the preparation of samples ([Table 4](#tbl4){ref-type="table"}). Incredibly, the TSI profiles of the zein nanosystems remained constant after 12 months of storage at 4 °C, confirming the properties of the colloidal structure that permit it to effectively interact and retain the drug with no sedimentation, flocculation or creaming phenomena across time.Table 4TSI values of SD-zein nanoparticles prepared with various amounts of PTX as a function of time and temperature.Table 4Time (days)20 °C37 °CEmptyPTX 100 μg/mlPTX 200 μg/mlPTX 300 μg/mlEmptyPTX 100 μg/mlPTX 200 μg/mlPTX 300 μg/ml03.423.854.854.922.893.064.715.0113.394.004.814.992.853.104.785.1053.513.924.775.102.993.154.894.98103.453.934.915.022.953.004.795.15153.473.914.954.982.943.174.845.18203.543.884.925.032.813.114.905.09253.553.844.875.052.853.074.855.17303.443.914.905.002.943.184.865.20

3.2. Influence of heating, serum incubation and pH on the particle stability {#sec3.2}
----------------------------------------------------------------------------

The knowledge of the effects of temperature on the stability of zein-based nanoformulations is an important parameter to be investigated because the systems may be subjected to heat during the manufacturing procedures, storage and administration ([@bib6]). The protective feature provided by SD was previously described by our research team, showing that surfactant-free zein nanoparticles dramatically increase their mean sizes at temperatures higher than 30 °C ([@bib20]). For this reason the nanosystems containing PTX were incubated at temperatures up to 50 °C and mean sizes, size distribution and surface charges were evaluated. [Table 5](#tbl5){ref-type="table"} shows that the average diameter of the particles remained relatively small but it is interesting to note the increased mean sizes of the particles prepared with the highest concentration of PTX. The evaluation of the polydispersity index confirmed this trend probably as a consequence of the steric hindrance exerted by the active compound. Contrarily, the surface charges of the nanosystems were not affected by the temperature, confirming the fundamental role of SD in their stabilization.Table 5Effect of heating on the physico-chemical parameters of zein nanoparticles containing various amounts of PTX.Table 5PTX concentration (μg/ml)Temperature (°C)Mean size (nm)Polydispersity IndexZeta potential (mV)-30126 ± 10.12 ± 0.01-33.8 ± 2.640126 ± 20.13 ± 0.02-34.7 ± 2.250128 ± 10.15 ± 0.02-28.9 ± 1.210030103 ± 60.19 ± 0.01-32 ± 1.140118 ± 50.22 ± 0.04-34 ± 1.550129 ± 6\*0.25 ± 0.05-30 ± 1.620030131 ± 60.18 ± 0.03-29 ± 1.240133 ± 60.19 ± 0.02-33 ± 1.550140 ± 50.21 ± 0.01-30 ± 1.330030158 ± 50.21 ± 0.04-31 ± 2.040160 ± 60.23 ± 0.05-32 ± 3.050160 ± 60.25 ± 0.06-31 ± 2.9[^8]

The zein nanoparticles containing PTX were also incubated in 70% FBS at various pH values with the aim of fully investigating their stability features. As can be seen in [Fig. 3](#fig3){ref-type="fig"}A the sizes of the nanosystems showed only a slight increase in the mean diameter with respect to the empty formulation when dispersed in serum, confirming the great compatibility of SD-stabilized zein nanoparticles with biological fluids ([@bib20]). The same trend was observed at different pH values, demonstrating the absence of macroaggregates when the ionic strength was varied ([Fig. 3](#fig3){ref-type="fig"}B). This data is in agreement with that reported in other investigations on the ability of sodium cholate derivatives to stabilize various polymeric colloidal structures ([@bib9]; [@bib37]).Fig. 3Influence of (A) serum (FBS, 70%) and (B) various values of pH on the stability of SD-stabilized zein nanoparticles containing PTX as a function of the drug concentration and incubation time.Fig. 3

3.3. Entrapment efficiency of PTX {#sec3.3}
---------------------------------

Another parameter to be evaluated in the phases of characterization of a colloidal system is its drug encapsulation efficiency, fundamental for the *in vitro* experiments. In order to determine the maximum amount of PTX that can be encapsulated in the zein nanoparticles, various concentrations of drug were used during the preparation process of the colloidal systems.

In [Table 6](#tbl6){ref-type="table"} the retention of PTX in the colloidal structure is shown as a function of the drug initially added; namely, the use of a concentration of PTX of 100 μg/ml favored an encapsulation of about 29% of the active compound, while the use of 200 μg/ml of anticancer agent showed an entrapment of approximately 32% of the lipophilic molecule. The best results were obtained at a drug concentration of 300 μg/ml because the amount of bioactive compound retained by the nanosystems was about 40%, representing the best condition to operate in terms of the cost/benefit ratio. Increasing amounts of PTX added during the preparation procedure of the zein nanoparticles promote a destabilization of the colloidal systems resulting in sediment and macroaggregates (data not shown). The results demonstrate a significant retention of the lipophilic drug providing a different encapsulation profile with respect to the data evidenced during our research concerning the encapsulation of other lipophilic compounds (ATRA and Red Oil) in SD-stabilized zein nanoparticles ([@bib29]; [@bib20]). This is probably due to the peculiar chemical structure of PTX, which renders it able to be perfectly integrated into the polymeric structure of the nanosystems. A validation of this hypothesis was provided by the evaluation of the drug release profiles from the zein nanoparticles; namely, the drug leakage was constant and prolonged ([Fig. 4](#fig4){ref-type="fig"}) and it was modulated by the amount of the entrapped active compound. In fact, the samples prepared using 100 and 200 μg/ml of PTX showed full release of the drug after 48 and 120 h, respectively, while the formulation containing the highest amount of the active compound was characterized by a release of PTX of ∼70% after 5 days of analysis ([Fig. 4](#fig4){ref-type="fig"}).Table 6Entrapment efficiency (EE%) and loading capacity (LC%) of various amounts of PTX in SD-stabilized zein nanoparticles prepared using a protein concentration of 2 mg/mL and 1.25% w/v of SD as a function of the drug concentration initially used.Table 6Amount of drug used (μg/ml)EE (%)LC (%)Amount of entrapped drug (μg/ml)10029 ± 30.9 ± 0.0329 ± 1.220032 ± 32.12 ± 0.1264.5 ± 2.330040 ± 43.84 ± 0.15120 ± 3.9Fig. 4Release profile of paclitaxel (PTX) from SD-stabilized zein nanoparticles as a function of the entrapped drug and time. Values represent the mean of three different experiments ± standard deviation.Fig. 4

3.4. Freeze-drying of PTX-loaded zein nanoparticles {#sec3.4}
---------------------------------------------------

The freeze-drying features of an innovative nanosystem are also critical aspects to be evaluated in order to provide long-term storage and stability of the formulation and its potential practical application ([@bib5]). As previously described, sodium deochycholate (SD) was proposed as a promising stabilizer for use in developing freeze-dried zein nanoparticles characterized by a high level of stability ([@bib20]). For this reason, additional lyophilization studies were performed on the nanoformulation prepared with 0.3 mg/ml of PTX in order to evaluate the influence of various cryoprotectants on the physico-chemical properties of the colloidal systems. As shown in [Table 7](#tbl7){ref-type="table"}, no significant differences in particle size, polydispersity index or zeta potential were observed when glucose (5% w/v), sucrose, mannitol and trehalose were used, suggesting the high stability and potential long-term storability of these formulations. Only when mannose and 10% w/v glucose was used did problems of redispersion of the samples and a discrete degree of aggregation occur, confirming the unsuitability of the saccharide in the development of acceptable freeze-dried zein nanoparticles ([Table 7](#tbl7){ref-type="table"}).Table 7Physico-chemical properties of zein nanoparticles prepared with a PTX concentration of 0.3 mg/ml as a function of different cryoprotectants after the freeze-drying process.Table 7CryoprotectantCryoprotectant concentration (% w/v)Mean size (nm)Polydispersity IndexZeta Potential (mV)Before lyophilization-110 ± 10.11 ± 0.01-34 ± 2.9\--\>1000\*\*0.9 ± 0.05-25 ± 1.8Glucose5%158 ± 6\*\*0.21 ± 0.03-39 ± 3.1Glucose10%450 ± 20\*\*0.89 ± 0.04-19 ± 0.1Mannose5%\>1000\*\*0.9 ± 0.08-21 ± 7.4Mannose10%500 ± 31\*\*0.66 ± 0.03-19 ± 8.2Trehalose5%150 ± 2\*\*0.19 ± 0.01-35 ± 2.7Trehalose10%166 ± 2\*\*0.25 ± 0.05-36 ± 2.6Sucrose5%175 ± 8\*\*0.27 ± 0.07-38 ± 5.2Sucrose10%190 ± 9\*\*0.29 ± 0.09-37 ± 3.3Mannitol5%160 ± 5\*\*0.24 ± 0.06-38 ± 2.1Mannitol10%180 ± 3\*\*0.19 ± 0.04-38 ± 3.9[^9]

3.5. Cytotoxicity of PTX-loaded zein nanoparticles {#sec3.5}
--------------------------------------------------

The evaluation of the cytotoxicity of a colloidal system is another fundamental parameter to be evaluated in the phases of preformulation ([@bib21]). The SD-stabilized zein nanosystems manifested a favorable safety profile towards various cell lines up to 50 μg/mL of protein ([@bib20]). For this reason, the pharmacological efficacy of the PTX-loaded zein nanosystems, obtained using 300 μg/ml of drug during the preparation procedure, was evaluated on K562 and MCF-7 cells, as models of human cancer cells sensitive to the lipophilic drug, with respect to the free form of the active compound ([Fig. 5](#fig5){ref-type="fig"}). The choice of this formulation was due to the favorable physico-chemical and technological features obtained during the characterization of the nanosystems. The cytotoxic effects were evaluated as a function of both the incubation times (24, 48, or 72 h) and the drug concentrations (0.1--1 μM) in order to define the exposition time and the dose-response effects, respectively.Fig. 5Evaluation of *in vitro* cytotoxicity of SD-stabilized zein nanoparticles containing PTX (prepared using 0.3 mg/ml of active compound) on MCF-7 and K562 cells as a function of the drug concentration and incubation time. Data are the percentages of cellular viability as evaluated by MTT-testing. Results are the mean of four different experiments ± standard deviation. \*p \< 0.05, \*\*p \< 0.001 (with respect to the untreated cells).Fig. 5

In detail, the nanoencapsulation of the anticancer agent promoted a greater decrease in cell viability as compared to the free form of PTX at all the concentrations used ([Fig. 5](#fig5){ref-type="fig"}); the best anticancer effects were exerted by the colloidal formulation containing the lipophilic drug on the MCF-7 cells because noteworthy pharmacological efficacy was shown early on during incubation. Contrarily, the increased toxicity of nanoencapsulated PTX on K562 cells was more evident only after 72 h ([Fig. 5](#fig5){ref-type="fig"}). The IC~50~ evaluation of the drug encapsulated within the colloidal systems confirmed the difference in pharmacological efficacy on the aforementioned cell lines ([Table 8](#tbl8){ref-type="table"}). The uptake of the nanosystems containing PTX could be a plausible explanation for the increased cytotoxic effect of the bioactive, as has been true in the case of many other polymeric carriers and it could favor a significant decrease of the efficacious concentration of the drug ([@bib33]).Table 8IC~50~ value of PTX and PTX-loaded zein nanoparticles as a function of cell lines and incubation time.Table 8Cell linesIncubation timeIC~50~ PTX (μM)IC~50~ PTX-loaded zein nanoparticles (μM)MCF-724 h\>1148 h\>10.4972 h0.550.05K56224 h\>1\>148 h\>1\>172 h0.720.19[^10]

In fact, the evaluation of the cell interaction rate of tritiated zein-nanoparticles confirmed a time-dependent cell uptake of the nanosystems that occurred after only 1 h incubation ([Fig. 6](#fig6){ref-type="fig"}). In addition, it was interesting to note that the interaction between the K562 cells and zein nanoparticles was less than that obtained in the case of MCF-7 cells, probably as a consequence of the physical deposition of the polymeric systems on the plate which promoted their accumulation in the adherent cells. It is well known that the cell uptake of polymeric nanoparticles having a mean diameter \<200 nm is characterized by an endocytotic mechanism ([@bib7]). It has been demonstrated that various zein nanoparticles are characterized by an energy-dependent cell uptake but the specific mechanisms governing the intracellular localization of the SD-zein nanosystems have not yet been investigated ([@bib30]).Fig. 6Interaction between \[^3^H\]CHE radiolabeled SD-stabilized zein nanoparticles and the different cancer cell lines as a function of incubation times. Results are the mean of three different experiments ± standard deviation. \*p \< 0.05, \*\*p \< 0.001.Fig. 6

Moreover, the influence of various surfactants on the inhibition of P-glycoprotein (P-gp) efflux pumps was described in recent experimental investigations ([@bib22]; [@bib1]); sodium deoxycholate could compromise the efficacy of P-gp promoting the pharmacological effects of PTX following its nanoencapsulation in SD-zein nanoparticles ([@bib40]; [@bib39]).

The results demonstrate that zein nanoparticles preclude the use of organic solvents to solubilize the lipophilic compound, which would mean a potential dramatic decrease in the side effects related to their use in human beings.

4. Conclusions {#sec4}
==============

The use of biomaterials to deliver traditional anticancer compounds is a widely-recognized approach for developing innovative nanomedicines characterized by a high level of pharmacological efficacy and decreased side effects. Moreover, the encapsulation of lipophilic compounds in colloidal systems promotes the modulation of their biopharmaceutical properties avoiding the use of organic solvents. The physical entrapment of PTX in zein nanoparticles demonstrated its potentiality for use as a novel anticancer formulation due to its properties of high stability and *in vitro* anticancer efficacy. Obviously, there are several sticking points in clinical translation that should be addressed, considering both the delivery (e.g., biological challenges) and regulatory aspects (e.g., study, design and approval challenges). In fact, there is a general lack of regulatory standards regarding the examination of nanoparticle-based therapeutics, so significant efforts are being made in this direction. For this reason, additional studies concerning the nature of the plasmatic proteins adsorbed on the colloidal surface after serum incubation/*in vivo* injection, and the biodistribution and pharmacokinetic profiles of the described formulation are in progress. Moreover, the investigation of the anticancer properties of PTX-loaded-SD-stabilized zein nanoparticles on murine tumor xenograft models will be evaluated in order to demonstrate the real efficacy of this nanomedicine in preclinical and clinical applications.
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[^1]: \*p \< 0.05, \*\*p \< 0.001 (with respect to the formulation F).

[^2]: Tween 80®.

[^3]: Poloxamer188®.

[^4]: Sodium deoxycholate.

[^5]: \*p \< 0.05, \*\*p \< 0.001 (with respect to the empty formulation).

[^6]: Sodium azide (0.05% w/v) was added to the formulations as preservative.

[^7]: \*p \< 0.05, \*\*p \< 0.001 (with respect to the empty formulation).

[^8]: \*p \< 0.05 (with respect to the formulation at 30 °C).

[^9]: \*\*p \< 0.001 (with respect to the formulation before the freeze-drying procedure).

[^10]: The values have been obtained fitting the MTT-test curves to the following Four Parameter Logistic Equation:$y = min + \frac{max - min}{1 + \left( \frac{x}{EC50} \right)Hillslop}$
